Jefferies Comments on Development at BioMed Realty Trust

Jefferies has published a research report on BioMed Realty Trust BMR updating on the status of the company. In the report, Jefferies wrote, "BMR reported essentially in-line 2Q11 results and narrowed its 2011 FFO per share guidance range by $0.01 at each end to a new range of $1.16-$1.20 from $1.15-$1.21 although the midpoint of $1.18 remains unchanged. The company has experienced strong leasing success related to its five quarter leasing goal (4Q10-4Q11) and is well positioned to capitalize on the over 3.5M sq. ft. of development potential in its portfolio." Jefferies rated BioMed Realty Trust a BUY with a price target of $20.00. BioMed Realty Trust closed Friday at $17.12.